L3VLUP
ProSign in

CYTK · JNJ in the 13F filings

Two to four stocks side by side among the 95 tracked managers: who lists them, how that has moved, who bought and sold in a quarter, and which managers hold more than one.

CYTKJNJ
Quarter
Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023

Holders over time

Tracked managers listing each stock every quarter, at least, or their combined reported value. A gap is a quarter in which no tracked manager listed it. Click a quarter to compare there.
  • CYTK
  • JNJ
0204060202120222023202420252026
Holders and value by quarter
QuarterCYTKJNJ
Q3 20205 holders, $114m30 holders, $26.2bn
Q4 20203 holders, $90m32 holders, $26.6bn
Q1 20213 holders, $90m31 holders, $25.3bn
Q2 20212 holders, $74m37 holders, $25.6bn
Q3 20217 holders, $643m40 holders, $24.1bn
Q4 202110 holders, $794m33 holders, $25.2bn
Q1 20226 holders, $624m35 holders, $28.2bn
Q2 202210 holders, $1.0bn33 holders, $26.9bn
Q3 20229 holders, $1.0bn36 holders, $25.4bn
Q4 202212 holders, $1.1bn35 holders, $27.6bn
Q1 202311 holders, $895m42 holders, $24.5bn
Q2 20238 holders, $781m38 holders, $25.0bn
Q3 202310 holders, $753m37 holders, $18.9bn
Q4 202312 holders, $2.4bn31 holders, $19.0bn
Q1 202415 holders, $1.8bn32 holders, $19.7bn
Q2 202416 holders, $1.5bn35 holders, $20.4bn
Q3 202415 holders, $1.5bn28 holders, $22.3bn
Q4 202411 holders, $1.1bn37 holders, $20.4bn
Q1 20259 holders, $544m32 holders, $20.5bn
Q2 20254 holders, $268m31 holders, $18.4bn
Q3 20256 holders, $1.3bn32 holders, $23.7bn
Q4 20258 holders, $1.5bn29 holders, $27.8bn
Q1 202611 holders, $1.5bn34 holders, $35.6bn
Q2 202612 holders, $1.3bn33 holders, $39.1bn
CYTK

Cytokinetics Inc

Holders
6
Reported value
$1.3bn
Buyers
4
Sellers
2

Breadth +2 among 95 comparable managers.

Pharmaceuticals and biotechnologyHealthcare: biopharma and medtech · L3VLUPPharmaceutical preparations
JNJ

Johnson & Johnson

Holders
32
Reported value
$23.7bn
Buyers
17
Sellers
13

Breadth +4 among 95 comparable managers.

Pharmaceuticals and biotechnologyHealthcare: biopharma and medtech · L3VLUPPharmaceutical preparations

Who holds both, Q3 2025

Among the 35 tracked managers listing any of them. "Only" is about listed positions: a manager may hold the other below its listed range.

Only CYTK (3)

Hudson Bay Capital Management LP, Moore Capital Management LP, Point72 Asset Management LP

Only JNJ (29)

Acadian Asset Management LLC, AllianceBernstein LP, AQR Capital Management LLC, Arrowstreet Capital LP, Balyasny Asset Management LLC, Brevan Howard Capital Management LP, Bridgewater Associates LP, Capital Research Global Investors, Caxton Associates LLP, Citadel Advisors LLC, D. E. Shaw & Co., Dodge & Cox, Freestone Grove Partners LP, GAMCO Investors Inc, Invesco Ltd, Jane Street Group LLC, Janus Henderson Group Ltd, Man Group PLC, Markel Group Inc, Marshall Wace LLP, MFS Investment Management, Millennium Management LLC, Neuberger Berman Group LLC, Renaissance Technologies LLC, Schonfeld Strategic Advisors LLC, and 4 more

How much of the picture this is

A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. Buyers and sellers count comparable managers (those that filed both quarters) by shares, so a rise in value with no rise in shares is the price. Large books are listed to their largest positions. These are 95 tracked managers, not the institutional market.

Back to the 13F Explorer →